Launching NEW GlyCLICK® ADC kits!

Genovis launches new GlyCLICK kits for site-specific generation of custom ADCs carrying unique 2-step cleavable linker-payloads from Glykos Finland. 

Antibody-drug conjugates (ADCs) comprise a new generation of antibody-based biologics that carry drug payloads directly into target cells, allowing for a broadened therapeutic window. The drawbacks of conventional antibody conjugation strategies are rapidly being surpassed by site-specific methods, where conjugation at the Fc-glycan sites using GlyCLICK has proven to be an attractive option for labeling of native antibodies without genetic engineering.

The GlyCLICK conjugation technology results in site-specific incorporation of 2.0 drugs per antibody, for this reason the GlyCLICK ADC kits offer conjugation with highly potent payloads functionalized with DBCO to enable click-chemistry to azide activated antibodies. GlyCLICK ADC kits can be used to combine native IgG with a two-step cleavable linker carrying either MMAE or PNU for the desired cytotoxic effect on targeted cells (Fig. 1).

Learn more about the GlyCLICK technology for ADC development.

GlyCLICK ADC kit MMAE – Site-specific ADC generation with cleavable linker-payloads carrying MMAE.

GlyCLICK ADC kit PNU – Site-specific ADC generation with cleavable linker-payloads carrying PNU.